13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001637359
Total reported value
$185.7M
$185.7M
11 檔
76.2%
At the close of Q3 2024, Omega Fund Management, LLC disclosed equity holdings valued at approximately $185.7M, spread across 11 reported holdings.
In Q3 2024, Omega Fund Management, LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 1 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc | Stock-Other | 35.09% | -0.02% | — | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 18.71% | +3.47% | -1.53% | |
| 3 | REPL | Replimune Group Inc | Stock-Other | 16.86% | -1.17% | EXIT | |
| 4 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 13.31% | — | — | |
| 5 | ✓ | Engene Holdings Inc | Stock-Other | 4.44% | -2.84% | — | |
| 6 | ALMS | Alumis Inc | Stock-Other | 4.36% | +0.40% | -0.00% | |
| 7 | ✓ | Ikena Oncology Inc | Stock-Other | 2.43% | — | — | |
| 8 | SANA | Sana Biotechnology Inc | Stock-Other | 2.19% | +0.10% | — | |
| 9 | VTLUSD | Immunic Inc | Stock-Other | 1.84% | — | — | |
| 10 | ✓ | Engene Holdings Inc | Stock-Other | 0.42% | — | — | |
| 11 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.34% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc | +35.1% | NEW | New buy |
| 2 | REPL | Replimune Group Inc | +0.5% | — | Unchanged |
| 3 | VTLUSD | Immunic Inc | +0.4% | — | Unchanged |
| 4 | ✓ | Engene Holdings Inc | +0.1% | — | Unchanged |
| 5 | ✓ | Ikena Oncology Inc | -0.3% | — | Unchanged |
| 6 | SYRS | Syros Pharmaceuticals Inc | -0.6% | — | Unchanged |
| 7 | SANA | Sana Biotechnology Inc | -1.2% | — | Unchanged |
| 8 | ALMS | Alumis Inc | -2.1% | -0.00% | Trim |
| 9 | ✓ | Engene Holdings Inc | -3.1% | — | Unchanged |
| 10 | MORFUSD | Morphic Holding Inc | -4% | EXIT | Sold out |
| 11 | NUVB | Nuvation Bio Inc | -10% | -1.53% | Trim |
| 12 | LXEO | Lexeo Therapeutics Inc | -14.7% | — | Unchanged |
According to official SEC Form 13F filings, Omega Fund Management, LLC reported a total U.S. public equity portfolio value of $185.7M across 11 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BCAX, NUVB, REPL) accounted for 76.2% of total reported equity market value during Q3 2024.
Top New Position Initiated
BCAX
市值: $56.2M
Top Position Liquidated / Trimmed
MORFUSD
前期市值: $5.4M
During Q3 2024, Omega Fund Management, LLC's top holdings by market value included BCAX (35.1%)、NUVB (18.7%)、REPL (16.9%). The largest single position, BCAX, represented 35.1% of total portfolio value.
In Q3 2024, Omega Fund Management, LLC made 4 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 2 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.